Advertisement

Dementia: Making a Diagnosis and Managing Behavioural and Psychological Symptoms

  • Brendan FlynnEmail author
Chapter
  • 1.3k Downloads

Abstract

  • Making a diagnosis of dementia can provide a degree of certainty about the future and allow for important personal, social and legal arrangements to be addressed.

  • The diagnosis of dementia rests on the clinical history, corroborative information, cognitive examination and evidence of functional decline.

  • The diagnosis is a clinical one—confirmation is only available by microscopic examination of neural tissue.

  • Person-centred care is an important principle in dementia care.

  • Non-pharmacological interventions should be tried first when treating behavioural or psychological symptoms of dementia.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Dementia factsheet; 2015. www.who.int/mediacentre/factsheets/fs362/en/.
  3. 3.
    O’Brien JT, Markus HS. Vascular risk factors and Alzheimer’s disease. BMC Med. 2014;12:218. doi: 10.1186/s12916-014-0218-y.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Loy CT, Schofield PR, Turner AM, Kwok JBJ. Genetics of dementia. Lancet. 2014;383:828–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke’s Cognitive Examination III in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;36:242–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Kang H, Zhao F, You L, Giorgetta C, Venkatesh D, Sarkhel S, Prakash R. Pseudo-dementia: a neuropsychological review. Ann Indian Acad Neurol. 2014;17:147–54. doi: 10.4103/0972-2327.132613.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm. 2015;122(4):505–21. doi: 10.1007/s00702-014-1288-x.CrossRefPubMedGoogle Scholar
  10. 10.
    Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA. 2004;292(23):2901–8. doi: 10.1001/jama.292.23.2901.CrossRefPubMedGoogle Scholar
  11. 11.
    Di Carlo A, Lamassa M, Baldereschi M, Inzitari M, Scafato E, Farchi G, Inzitari D. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007;68:1909–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, Wallace RB. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148:427–34.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8. [Erratum, Arch Neurol. 1999;56:760]CrossRefPubMedGoogle Scholar
  14. 14.
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9. doi: 10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151–7. doi: 10.1001/archneurol.2009.106.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44. doi: 10.1056/NEJMra0909142.CrossRefPubMedGoogle Scholar
  17. 17.
    Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011;10(7):667–70. doi: 10.1016/S1474-4422(11)70123-5.CrossRefPubMedGoogle Scholar
  18. 18.
    Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci. 2015;9:345. doi: 10.3389/fnins.2015.00345.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Gupta D, Kuruvilla A. Vascular parkinsonism: what makes it different? Postgrad Med J. 2011;87:829–36. doi: 10.1136/postgradmedj-2011-130051.CrossRefPubMedGoogle Scholar
  21. 21.
    O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386:1698–706. doi: 10.1016/S0140-6736(15)00463-8.CrossRefPubMedGoogle Scholar
  22. 22.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Warren JD, Rohrer JD, Rossor MN. Frontotempoeral dementia. BMJ. 2013;347:f4827. doi: 10.1136/bmj.f4827.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IRA, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73(18):1451–6. doi: 10.1212/WNL.0b013e3181bf997a.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Turnbull Q, Wolf AMD, Holroyd S. Attitudes of elderly subjects toward “Truth Telling” for the diagnosis of Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2002;16:90–3. doi: 10.1177/0891988703016002005.CrossRefGoogle Scholar
  26. 26.
    Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312(23):2551–61. doi: 10.1001/jama.2014.13806.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. NICE technology appraisal guidance 217; 2011. http://guidance.nice.org.uk/TA217.
  28. 28.
    Burns A, Yeates A, Akintade L, del Valle M, Zhang RY, Schwam EM, Perdomo CA. Defining treatment response to donepezil in Alzheimer’s disease: responder analysis of patient-level data from randomized, placebo-controlled studies. Drugs Aging. 2008;25(8):707–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Atri A, Hendrix SB, Pejović V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28. doi: 10.1186/s13195-015-0109-2.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2:e000917. doi: 10.1136/bmjopen-2012-000917.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Stinton C, McKeith I, Taylor J, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O’Brien JT. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731–42. doi: 10.1176/appi.ajp.2015.14121582.CrossRefPubMedGoogle Scholar
  32. 32.
    Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–50. doi: 10.1002/mds.22322.CrossRefPubMedGoogle Scholar
  33. 33.
    Brodaty H, Draper BM, Low L. Behavioural and psychological symptoms of dementia: a seven tiered model of service delivery. Med J Aust. 2003;178(5):231–4.PubMedGoogle Scholar
  34. 34.
    NSW Ministry of Health and Royal Australian and New Zealand College of Psychiatrists. Assessment and management of people with Behavioural and Psychological Symptoms of Dementia (BPSD): a handbook for NSW Health Clinicians; 2013. Accessible via www.health.nsw.gov.au or www.ranzcp.org.
  35. 35.
    International Psychogeriatric Association. Thee IPA complete guides to behavioral and psychological symptoms of dementia; 2012. www.ipa-online.org.
  36. 36.
    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335–41. doi: 10.1056/NEJMoa052827.CrossRefPubMedGoogle Scholar
  37. 37.
    Kleijer BC, van Marum RJ, Egberts ACG, Jansen PAF, Frijters D, Heerdink ER, Ribbe MW. The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. Int Psychogeriatr. 2009;21:931–40. doi: 10.1017/S1041610209990524.CrossRefPubMedGoogle Scholar
  38. 38.
    Finkel SI, Lyons JS, Anderson RL. A Brief Agitation Rating Scale (BARS) for nursing home elderly. J Am Geriatr Soc. 1993;41(1):50–2. doi: 10.1111/j.1532-5415.1993.tb05948.x.CrossRefPubMedGoogle Scholar
  39. 39.
    Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214–9. doi: 10.1212/01.WNL.0000129990.32253.7B.CrossRefPubMedGoogle Scholar

Copyright information

© The Editor(s)  2018

Authors and Affiliations

  1. 1.Conjoint Senior Lecturer, University of NewcastleNewcastleAustralia
  2. 2.Director of Medical Services, Hunter New England Mental Health, Hunter New England Local Health DistrictNewcastleAustralia

Personalised recommendations